Pre-surgery chemo plus oral hydroxychloroquine for pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies giving chemo and hydroxychloroquine before surgery for resectable pancreatic cancer. The goal is to shrink the tumor and improve the chances of successful removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer proven by biopsy (tissue sample).
- Your scans show the cancer can be fully removed with surgery (no major blood-vessel involvement or distant spread).
- You are well enough to do normal activities most of the time (ECOG 0–1).
- Your blood tests and organ function (kidneys, liver, and blood counts) are within allowed ranges.
- You have not had chemotherapy in the last 12 months, and you have not had radiation or study drugs for pancreatic cancer before.
- You can safely take the study medicines (no serious drug allergies; no pregnancy; certain specific genetic risks and conditions exclude some people).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
This trial tests a combination of chemotherapy drugs (mFOLFIRINOX) given before surgery to people with pancreatic cancer that may be removable. The goal is to see if this approach works well and to prepare for a larger study.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Hear when a new Adenocarcinoma of the Pancreas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.